Hydroxyurea: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Hydroxyurea. Educational only — not medical advice.
Labeled uses
Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.
Source: FDA labeling via NIH DailyMed (set 7a2e2305…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.